Home

Amgen

Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer

Amgen (Nasdaq: AMGN) today announced positive top-line results from a Phase 3 trial evaluating Vectibix((R) )(panitumumab) in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients with metastatic colorectal cancer (mCRC). The co-primary endpoints, tested independently, were progression-free and overall survival.

HSN Goes Mobile With Apple iPhone

HSN (hsn.com), the leading interactive lifestyle network and retail destination, announces today the launch of a dynamic new application ("app") for the Apple(R) iPhone(TM) and iPod(R) touch(R). The 45 million subscribers to the devices who download the HSN Shop App now have the ability to view HSN programming 24 hours a day, 7 days a week, throughout the US. The launch creates the e-commerce industry's first live-video "3-screen experience," enabling consumers to browse and shop the network's 35,000-plus array of products from home or on the go.